Houlihan Lokey FY2026 slides: record revenue amid market leadership

Houlihan Lokey reported fiscal 2026 revenue of $2.618B, up 10% year over year, and adjusted EPS of $7.56, up 20%, despite a Q4 EPS miss at $1.63 versus $1.79 expected. The firm guided to revenue of $2.95B and EPS of $7.96 for fiscal 2027, with its dividend raised for 11 consecutive years and yielding 1.88%. The presentation highlighted strong positions in M&A, restructuring, and sponsor advisory, though the stock reaction was limited to a 2.22% after-hours gain.

Analysis

HLI is one of the cleaner ways to express a late-cycle fee pool trade without taking balance-sheet risk. The mix shift toward corporate finance makes the equity less countercyclical than in prior years, but it also raises the quality of the earnings stream because sponsor-backed and mid-market advisory work tends to recover faster than broad capex or underwriting cycles. The market is still discounting the stock like a plain-vanilla financials compounder; the more important lens is that HLI’s earnings are being levered to private equity exit pressure, not GDP alone.

The second-order bull case is that aging sponsor portfolios create a self-reinforcing pipeline: the longer holding periods persist, the more demand accrues for sell-side, recap, and valuation work, while the firm’s sponsor coverage becomes a distribution channel into repeat mandates. That dynamic should also help Capital Solutions, where the real economic value is not just financing fees but control of the process when traditional bank lending is constrained. If credit tightens modestly, HLI’s restructuring revenue can offset softness in M&A, but the bigger upside comes if spread volatility increases without a full recession.

The main risk is that consensus may be overestimating linear EPS compounding from share gains. At this valuation, the stock needs both continued mid-market market-share gains and stable staffing productivity; any deterioration in managing director retention or a re-acceleration in compensation pressure would hit margins quickly. A slower-than-expected PE exit window would defer revenue into 2027-2028 rather than destroy it, but that would still be enough to compress multiple expansion in the near term.

In the broader group, HLI’s relative resilience is modestly negative for advisory peers with weaker sponsor franchises and more cyclical exposure. GS, JPM, MS, and UBS are not direct comparables on mix, but HLI’s stronger pricing discipline and lower capital intensity imply that if mid-cap M&A stays active, the smaller pure-play advisors should re-rate first. PJT remains the cleaner hedge if one wants restructuring beta without paying for HLI’s corporate finance premium.

Key Decisions for Investors

• Long HLI on a 3-6 month horizon; favor entry on any 3-5% pullback. Upside case is low-to-mid teens total return if the market buys the 2027 EPS ramp, while downside is buffered by dividend support and recurring sponsor flow.
• Pair trade: long HLI / short a weaker advisory peer basket over 1-2 quarters. Thesis: HLI’s sponsor franchise and segment diversification should outperform firms with more event-driven revenue if deal activity stays choppy.
• Buy HLI Jan-2027 call spreads to express multiple expansion without paying full premium for near-term quarter noise. Risk/reward improves if consensus begins to anchor on the 2028 revenue run-rate rather than the latest quarterly miss.
• For restructuring beta, prefer PJT as a relative-value hedge against a recessionary downside scenario. HLI is the better all-weather compounder; PJT offers cleaner convexity if credit deterioration becomes the dominant macro variable.
• Avoid chasing the stock after guidance-driven rallies until the market confirms margin stability in the next two quarters. The key risk to the thesis is compensation creep, which can mute operating leverage faster than revenue growth can offset it.